We're sorry, but this trial is no longer enrolling volunteers.
A Phase III Double Blind Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-8742 in Subjects With Chronic HCV GT1, GT4 and GT6 Infection With Inherited Blood Disorders With and Without HIV Co-Infection
Description
Phase
Phase 3 - a treatment has shown activity against a particular disease, where it is either added to existing treatment or compared to the standard treatment.
Inclusion and Exclusion Criteria
- Has HCV GT1, GT4, or GT6 with sickle cell anemia, thalassemia, or hemophilia/von Willebrand disease
- Has cirrhosis or is non-cirrhotic
- Human immunodeficiency virus (HIV) coinfected or not infected with HIV
- Is a female of non childbearing potential, or is male or female and uses an acceptable method(s) of contraception
- Has evidence of decompensated liver disease
- Is coinfected with hepatitis B
- Has had a malignancy ≤5 years prior to signing informed consent except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
- Has hepatocellular carcinoma (HCC) or is under evaluation for HCC
- Has clinically-relevant drug or alcohol abuse within 12 months of screening
Sites
-
California
- Call for Information (Investigational Site 0326), Los Angeles, California, 90033
-
Texas
- Call for Information (Investigational Site 0316), Dallas, Texas, 75390
-
Indiana
- Call for Information (Investigational Site 0308), Indianapolis, Indiana, 46202
Powered by
SC CTSI